Skip to content

Management of Type-2 Diabetes mellitus and Prevention of Vascular Complications

Evaluation of safety and efficacy profile of Airborn Ultrasound in the Management of Type-2 Diabetes Mellitus and Associated Neurovascular Complications.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/014259
Enrollment
250
Registered
2018-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Suffering from Type-2 Diabetes Mellitus

Interventions

Intervention1: Low Frequency Airborn Ultrasound: The study will be conducted in accordance with the principles of GCP guidelines. The investigator will screen type 2 diabetic patients. Member of the i

Sponsors

Ms Maser Electronics Pvt Ltd
Lead Sponsor
Dr H S Gill
Collaborator
Dr Harish M Pathak
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with type 2 diabetes 2. Patients with HbA1c >7.5% 3. Patients with/without diabetic neuropathy 5. Patients willing to give written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patient with type 1 diabetes 2. Patientwith stents/pacemaker/CABG/advance cardiomyopathy 3. Patients with hepatic diseases 4. Patients with chronic kidney diseases 5. Patient taking immunosuppressive medications, glucocorticoids 6. Patient with chronic alcoholism/drug abuse 7. Pregnant & lactating women 8. Patients not willing to come for follow up as per protocol. 9. Patients who have participated in any other clinical study over the past 3 months.

Design outcomes

Primary

MeasureTime frame
Reduces the glycemic index as well as pro-inflammatory cytokines like IL6, TNF-alpha, hsCRP. It also reduced the elevated level of homocysteine and increased the level of vitamin D3. The patients reported feeling of well being, improve in appetite and sleep pattern.Timepoint: Gradual Improvement (1 month to 3 months)

Secondary

MeasureTime frame
Improvement in Glycemic Index and reduction in diabetic complications.Timepoint: Gradual Improvement (1 month to 3 months)

Countries

India

Contacts

Public ContactDr Manoj Kumar Pathak

Institute of Medical Sciences, Banaras Hindu University

gpdubey13@gmail.com9450963942

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026